Creating Better Medicines through Better Conjugation

Clinical-stage biopharmaceutical company Ambrx leverages its site-specific bioconjugation technology through partnerships to bring drugs with enhanced stability and bioactivity to market.

from BioPharm International’s 2013 Innovation Updates and Strategies eBook.